Chris Boshoff: Pfizer announced a 5-year update from our Phase 3 study for patients with ALK+ advanced NSCLC
Chris Boshoff, Chief Oncology Officer and Executive Vice President at Pfizer, shared on LinkedIn:
“Today at ASCO24, I am thrilled to share that Pfizer announced a 5-year update from our Phase 3 study, showing unprecedented results for patients with ALK+ advanced NSCLC. Read more here.
ALK+ advanced NSCLC is typically aggressive and often impacts younger people in the prime of their lives. I have had the privilege to see how our precision medicines have had a positive impact for patients since the discovery of the first ALK inhibitor more than 10 years ago.
The results being presented today, show that a majority of patients are living beyond five years without disease progression, representing Pfizer’s commitment to making significant progress in the treatment of this disease. .
Thank you to all the Pfizer colleagues, investigators, patients and their families who had a role in the trial and contributed to this milestone. It is a great honor to see the culmination of this work shared with the community.”
Source: Chris Boshoff/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023